Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company's commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer's disease. Its pre-clinical development programs comprise ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer's disease; ALPHA-1062 sublingual formulation for acute pancreatitis; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mild traumatic brain injury; and ALPHA-0602, ALPHA-0702, and ALPHA-0802 programs for the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis disease and spinal muscular atrophy. The company was founded in 2000 and is headquartered in Vancouver, Canada. Show more

Location: 750 West Pender Street, Vancouver, BC, V6C 2T8, Canada | Website: https://www.alphacognition.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

131.9M

52 Wk Range

$3.75 - $11.54

Previous Close

$8.16

Open

$8.17

Volume

42,585

Day Range

$8.08 - $8.46

Enterprise Value

84.24M

Cash

39.41M

Avg Qtr Burn

-3.016M

Insider Ownership

12.97%

Institutional Own.

35.39%

Qtr Updated

06/30/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.